Background {#Sec1}
==========

Gastric cancer is the second most common malignancy and the third most common cause of cancer-related death in China, with an estimated 423,500 newly diagnosed cases and 298,500 deaths in 2012 \[[@CR1]\]. Radical surgery followed by adjuvant chemotherapy is the mostly used strategy for management of gastric cancer. Nevertheless, the overall 5-year survival rate is still below 50% \[[@CR2]\], which may result from the insensitivity and/or tolerance to chemotherapy in some gastric cancer patients. Consequently, screening effective biomarkers has become a hot topic in the field of gastric cancer in order to develop individualized therapies and make patients obtain more beneficial effects.

Recently, several studies have suggested that the expressions of excision repair cross complementing 1 (ERCC1), breast cancer susceptibility gene breast cancer 1 (BRCA1), thymidylate synthetase (TYMS), ribonucleotide reductase M1 (RRM1), β-tubulin III (TUBB3), stathmin1 (STMN1) and topoisomerase IIα (TOP2A) genes are differential in cancer tissues and are closely associated with the clinicopathological characteristics of patients (such as clinical staging or lymphatic metastasis), which make them suitable to act as possible biomarkers to evaluate the therapeutic response and survival rates of cancer patients \[[@CR3]--[@CR8]\]. Although mounting evidence also indicates their important roles in gastric cancer \[[@CR9]--[@CR15]\], no study, to our knowledge, has been conducted to simultaneously detect their expressions in the samples of gastric cancer like other cancers \[[@CR3]--[@CR8]\].

In addition, genetic polymorphisms also possess important clinical values in predicting a susceptibility to cancer and the ability of an individual to respond to therapeutic agents. For example, UDP-glucuronosyltransferases (UGTs) are important enzymes responsible for glucuronidation of serum bilirubin, which is a natural antioxidant. The inter-individual variation in enzyme activity of UGT1A1 isozyme due to the polymorphisms at positions −3156 (G \> A), 211 (G/A) and TATA Box (6TAA/7TAA) leads to the lack of bilirubin and the development of cancer \[[@CR16], [@CR17]\]. UGTs also can transform toxic components (chemotherapy drugs) to less or nontoxic hydro-soluble forms, resulting in the failure or resistance of chemotherapy \[[@CR18]\]. Although there have reports to investigate the relationship between UGT1A1 polymorphisms and chemotherapy drug (irinotecan) toxicity or response \[[@CR19]--[@CR21]\], no studies have been performed to explore the association of UGT1A1 polymorphisms with clinicopathological features, which was the goal of our study.

The present study aims to detect the UGT1A1 polymorphisms and expressions of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in the tumor tissues from gastric cancer patients and explore their relationships with the clinicopathological characteristics, hoping to provide guidance for targeted cancer therapies individually.

Methods {#Sec2}
=======

Tissue samples {#Sec3}
--------------

A total of 98 tissue specimens were collected from gastric cancer patients in our hospital between May 2012 and March 2015. The samples were formalin-fixed paraffin-embedded (FFPE) or fresh frozen after radical surgery. All of them were histologically confirmed by two independent, experienced pathologists. All patients had complete medical records and no patient received neoadjuvant treatments prior to the primary surgery. All patients gave written informed consents for sample retention, analysis for research purposes and paper publication. The study protocol was approved by the ethics committee of Chengdu Military General Hospital of PLA, China.

Detection of mRNA expression levels {#Sec4}
-----------------------------------

A multiplex branched DNA liquidchip (MBL) technology (Guangzhou SurExam Bio-Tech Co., Ltd., China) was used for quantitative determination of all the genes at the mRNA level in the tissue samples simultaneously as previously reported \[[@CR3], [@CR22], [@CR23]\]. Briefly, the tissue samples were lysed in buffer at 56 °C for 2 h. The lysed product was transferred to a 96-well plate in which blocking reagent, capture beads and target gene-specific probe sets were included, and then incubated at 55 °C overnight on a shaker, followed by adding the hybridization mixture. Signals for bound target mRNA were amplified with streptavidin‑phycoerythrin at 50 °C for 30 min. The fluorescence value of each sample was recognized and analyzed by the Luminex 200 system (Luminex, Austin, TX, USA) to represent the mRNA expression level of each gene. The expression level of each gene was divided into low expression (\<25%), middle expression (25 \~ 75%) and high expression (\>75%) by comparing to the cut‑off value of each gene which was provided by Guangzhou Surexam Medical Test Center \[[@CR24]\].

UGT1A1 polymorphism analysis {#Sec5}
----------------------------

DNA was extracted from tissue samples using a phenol-chloroform method. Single nucleotide polymorphisms for the TATA box of the promoter (UGT1A1\*28, 6TAA/7TAA) and exon 1 (−211 G/A) were simultaneously determined with the PCR primer sequences as follows: 5'-ATTAACTTGGTGTATCGATTGG-3' and 5'-AAGCATAGCAGAGTCCTTTTTTA-3'\[[@CR25]\], while the PCR primer sequences for the phenobarbital responsive enhancer module region of the promoter (−3156 G/A) were 5'-CTGGGGATAAACATGGGATG-3' and 5'- CACCACCACTTCTGGAACCT-3' \[[@CR26]\]. Direct sequencing was performed using the ABIPRISM310 Genetic Analyzer (Applied Biosystems, Foster City, CA) according to standard protocols.

Statistical analysis {#Sec6}
--------------------

Statistical analyses were conducted using the SPSS v.19.0 statistical software (SPSS, Chicago, IL, USA). Statistically significant differences were evaluated by the chi-square test for categorical variables and *t*-test for continuous variables. *P* value of \< 0.05 was considered statistically significant.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

The patient characteristics are summarized in Table [1](#Tab1){ref-type="table"} (raw data see Additional file [1](#MOESM1){ref-type="media"}). Of the 98 patients, 76 (77.6%) were males and 22 (22.4%) were females. Ages of patients ranged from 32 to 77 years, with a mean of 56.92 ± 10.15 years. Thus, patients were stratified into two age groups (age \> 57 years and age \< 57 years). Histologically, all 98 lesions were classified into tubular adenocarcinoma (*n* = 75) and non-tubular adenocarcinoma (including mucinous adenocarcinoma, *n* = 21; and other types, *n* = 2). Further, samples with tubular adenocarcinoma was respectively shown to be well, moderately or poorly differentiated in 1, 21 and 53 patients, while the mucinous adenocarcinoma included poor differentiation and un-differentiation in 6 and 15 patients, respectively. Metastasis, including lymph node and distant involvement, was present in 55 (56.1%) patients. Approximately 81% (79/98) of the patients were diagnosed with a three- or four-level invasion depth. According to the 2002 AJCC TNM staging criteria \[[@CR27]\], patients were classified as stage I (18, 18.4%), II (29, 29.6%), III (39, 39.8%) and IV (12, 12.2%) tumor. Thirty-two patients had the history of alcohol intake and most of the patients (93%) did not have the family history of gastric cancer.Table 1Characteristics of 98 gastric cancer patientsCharacteristicCases, *n* (%)Gender Male76 (77.6) Female22 (22.4)Age  \< 57 years41 (41.8)  \> 57 years57 (58.2)Family history Yes5 (5.1) No93 (94.9)Alcohol history Yes32 (32.7) No66 (67.3)Histological type Tubular adenocarcinoma75 (76.5) Non-tubular adenocarcinoma23 (23.5)Differentiation Undifferentiated15 (15.3) Poor60 (61.2) Moderate22 (22.4) Well1 (1.0)Growth patterns Expansive2 (2.0) Invasive71 (72.4) Expansive + invasive25 (25.5)Depth of invasion T114 (14.3) T25 (5.1) T33 (3.1) T476 (77.6)Lymph node metastasis N052 (53.1) N132 (32.7) N211 (11.2) Undetermined3 (3.1)Distant metastasis M086 (87.8) M112 (12.2)TNM staging I18 (18.4) IIA-IIC29 (29.6) IIIA-IIIC39 (39.8) IVA-IVB12 (12.2)

Gene expression and their relationships with clinical characteristics {#Sec9}
---------------------------------------------------------------------

There were no significant associations between all 12 clinicopathological characteristics and the expressions of ERCC1, BRCA1, RRM1 and TOP2A. The expressions of TYMS (Table [2](#Tab2){ref-type="table"}), TUBB3 and STMN1 (Table [3](#Tab3){ref-type="table"}) were found to be correlated with age, in which patients with age \< 57 years exhibited lower expressions of TYMS (*P* = 0.044), TUBB3 (*P* = 0.024) and STMN1 (*P* = 0.042). Furthermore, lower expression of TUBB3 was observed in female patients (*P* = 0.026) and patients having a family history of gastric cancer (*P* = 0.025) (Table [3](#Tab3){ref-type="table"}). Similar to ERCC1, BRCA1, RRM1 and TOP2A, no correlations were also seen between clinicopathological characteristics of differentiation, growth patterns, metastasis and TNM staging, and the expression levels of TYMS, TUBB3 and STMN1 (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}).Table 2Relationships between gene expression and clinical characteristicsClinical featuresERCC1BRCA1TYMSRRM1LowMiddleHighLowMiddleHighLowMiddleHighLowMiddleHighGender Male11 (14.5)46 (60.5)19 (25.0)6 (7.9)39 (51.3)31 (40.8)24 (31.6)36 (47.4)16 (21.1)45 (31.6)25 (31.6)6 (31.6) Female6 (27.3)8 (36.4)8 (36.4)3 (13.6)11 (50.0)8 (36.4)6 (27.3)9 (40.9)7 (31.8)7 (31.6)11 (31.6)4 (31.6)*χ* ^2^, *P*4.219, .2190.702, 0.7041.101, 0.5775.541, 0.063Age  \< 57 years7 (17.1)19 (46.3)15 (36.6)6 (14.6)22 (53.7)13 (31.7)18 (43.9)14 (34.1)9 (22.0)20 (48.8)19 (46.3)2 (4.9)  \> 57 years10 (17.5)35 (61.4)12 (21.1)3 (5.3)28 (49.1)26 (45.6)12 (21.1)31 (54.4)14 (24.6)32 (56.1)17 (29.8)8 (14.0)*χ* ^2^, *P*3.073, 0.2153.535, 0.1716.264, **0.044**3.974, 0.137Family history Yes0 (0.0)3 (60.0)2 (40.0)1 (20.0)3 (60.0)1 (20.0)2 (40.0)2 (40.0)1 (20.0)2 (40.0)3 (60.0)0 (0.0) No17 (18.3)51 (54.8)25 (26.9)8 (8.6)47 (50.5)38 (40.9)28 (30.1)43 (46.2)22 (23.7)50 (53.8)33 (35.5)10 (10.8)*χ* ^2^, *P*2.065, 0.3561.219, 0.5440.209, 0.9011.889, 0.389Alcohol history Yes6 (18.8)18 (56.3)8 (25.0)2 (6.3)15 (46.9)15 (46.9)7 (21.9)17 (53.1)8 (25.0)15 (46.9)14 (43.8)3 (9.4) No11 (16.7)36 (54.5)19 (28.8)7 (10.6)35 (53.0)24 (36.4)23 (34.8)28 (42.4)15 (22.7)37 (56.1)22 (33.3)7 (10.6)*χ* ^2^, *P*0.178, 0.9151.204, 0.5481.770, 0.4131.011, 0.603Histological type Tubular adenocarcinoma14 (18.7)40 (53.3)21 (28.0)6 (8.0)37 (49.3)32 (42.7)20 (26.7)36 (48.0)19 (25.3)40 (53.3)26 (34.7)9 (12.0) Non-tubular adenocarcinoma3 (13.0)14 (60.9)6 (26.1)3 (13.0)13 (56.5)7 (30.4)10 (43.5)9 (39.1)4 (17.4)12 (52.2)10 (43.5)1 (4.3)*χ* ^2^, *P*0.526, 0.7691.328, 0.5152.400, 0.3011.387, 0.500Differentiation Undifferentiated2 (13.3)8 (53.3)5 (33.3)2 (13.3)8 (53.3)5 (33.3)7 (46.7)5 (33.3)3 (20.0)7 (46.7)8 (53.3)0 (0.0)  Poor10 (16.7)33 (55.0)17 (28.3)4 (6.7)32 (53.3)24 (40.0)15 (25.0)31 (51.7)14 (23.3)31 (51.7)23 (38.3)6 (10.0)  Moderate4 (18.2)13 (59.1)5 (22.7)3 (13.6)10 (45.5)9 (40.9)8 (36.4)9 (40.9)5 (22.7)14 (63.6)5 (22.7)3 (13.6)  Well1 (100.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (100.0)0 (0.0)0 (0.0)1 (100.0)0 (0.0)0 (0.0)1 (100.0)*χ* ^2^, *P*4.132, 0.6593.350, 0.7646.067, 0.41610.825, 0.094Growth patternsExpansive0 (0.0)0 (0.0)2 (100.0)0 (0.0)0 (0.0)2 (100.0)2 (100.0)0 (0.0)0 (0.0)1 (50.0)1 (50.0)0 (0.0) Invasive11 (15.5)41 (57.7)19 (26.8)7 (9.9)34 (47.9)30 (42.3)18 (25.4)33 (46.5)20 (28.2)34 (47.9)30 (42.3)7 (9.9) Expansive + invasive6 (24.0)13 (52.0)6 (24.0)2 (8.0)16 (64.0)7 (28.0)10 (40.0)12 (48.0)3 (12.0)17 (68.0)5 (20.0)3 (12.0)*χ* ^2^, *P*6.1410.1895.7440.2198.4380.0774.7650.312Depth of invasion T12 (14.3)5 (35.7)7 (50.0)1 (7.1)8 (57.1)5 (35.7)7 (50.0)4 (28.6)3 (21.4)9 (64.3)4 (28.6)1 (7.1) T22 (40.0)2 (40.0)1 (20.0)0 (0.0)2 (40.0)3 (60.0)2 (40.0)2 (40.0)1 (20.0)2 (40.0)2 (40.0)1 (20.0) T31 (33.3)2 (66.6)0 (0.0)0 (0.0)0 (0.0)3 (100.0)0 (0.0)1 (33.3)2 (66.6)2 (66.6)0 (0.0)1 (33.3) T412 (15.8)45 (59.2)19 (25.0)8 (10.5)40 (52.6)28 (36.8)21 (27.6)38 (50.0)17 (22.4)39 (51.3)30 (39.5)7 (9.2)*χ* ^2^, *P*7.2410.2997.5990.2696.7970.3404.8390.621Lymph node metastasis N010 (19.2)28 (53.8)14 (26.9)3 (5.8)30 (57.7)19 (36.5)18 (34.6)22 (42.3)12 (23.1)29 (55.8)19 (36.5)4 (7.7) N15 (15.6)18 (56.3)9 (28.1)3 (9.4)14 (43.8)15 (46.9)8 (25.0)15 (46.9)9 (28.1)14 (43.8)15 (46.9)3 (9.4) N21 (9.1)7 (63.6)3 (27.3)2 (18.2)6 (54.5)3 (27.3)3 (27.3)7 (63.6)1 (9.1)6 (54.5)2 (18.2)3 (27.3) Undetermined1 (33.3)1 (33.3)1 (33.3)1 (33.3)0 (0.0)2 (66.7)1 (33.3)1 (33.3)1 (33.3)3 (100.0)0 (0.0)0 (0.0)*χ* ^2^, *P*1.5380.9577.9790.2403.2620.7759.0430.172Distant metastasis M015 (17.4)48 (55.8)23 (26.7)7 (8.1)45 (52.3)34 (39.5)28 (32.6)38 (44.2)20 (23.3)44 (51.2)33 (38.4)9 (10.5) M12 (16.7)6 (50.0)4 (33.3)2 (16.7)5 (41.7)5 (41.7)2 (16.7)7 (58.3)3 (25.0)8 (66.7)3 (25.0)1 (8.3)*χ* ^2^, *P*0.227, 0.8930.954, 0.6211.460, 0.4821.065, 0.587TNM staging I4 (22.2)6 (33.3)8 (44.4)1 (5.6)10 (55.6)7 (38.9)9 (50.0)5 (27.8)4 (22.2)11 (61.1)5 (27.8)2 (11.1) IIA-IIC5 (17.2)19 (65.5)5 (17.2)2 (6.9)16 (55.2)11 (37.9)7 (24.1)15 (51.7)7 (24.1)16 (55.2)11 (37.9)2 (6.9) IIIA-IIIC6 (15.4)23 (59.0)10 (25.6)4 (10.3)19 (48.7)16 (41.0)12 (30.8)18 (46.2)9 (23.1)17 (43.6)17 (43.6)5 (12.8) IVA-IVB2 (16.7)6 (50.0)4 (33.3)2 (16.7)5 (41.7)5 (41.7)2 (16.7)7 (58.3)3 (25.0)8 (66.7)3 (25.0)3 (8.3)*χ* ^2^, *P*5.876, 0.4371.598, 0.9535.308, 0.5053.393, 0.758The values in bold indicate the statistically significant difference Table 3Relationships between gene expression and clinical characteristics (Continued Table 2)Clinical featuresTUBB3STMN1TOP2ALowMiddleHighLowMiddleHighLowMiddleHighGender Male22 (28.9)41 (53.9)13 (17.1)27 (35.5)36 (47.4)13 (17.1)9 (11.8)45 (59.2)22 (28.9) Female13 (59.1)8 (36.4)1 (4.5)7 (31.8)12 (54.5)3 (13.6)5 (22.7)11 (80.0)6 (27.3)*χ* ^2^, *P*7.280, **0.026**0.373, 0.8301.685, 0.431Age  \< 57 years21 (51.2)16 (39.0)4 (9.8)19 (46.3)19 (46.3)3 (7.3)8 (19.5)24 (58.5)9 (22.0)  \> 57 years14 (24.6)33 (57.9)10 (17.5)15 (26.3)29 (50.9)13 (22.8)6 (10.5)32 (56.1)19 (33.3)*χ* ^2^, *P*7.464, **0.024**6.361, **0.042**2.453, 0.293Family history Yes4 (80.0)0 (0.0)1 (20.0)2 (40.0)3 (60.0)0 (0.0)2 (40.0)2 (40.0)1 (20.0) No31 (33.3)49 (52.7)13 (14.0)32 (34.4)45 (48.4)16 (17.2)12 (12.9)54 (58.1)27 (29.0)*χ* ^2^, *P*7.414, **0.025**1.839, 0.3992.128, 0.345Alcohol history Yes10 (31.3)17 (53.1)5 (15.6)12 (37.5)13 (40.6)7 (21.9)3 (9.4)18 (56.3)11 (34.4) No25 (37.9)32 (48.5)9 (13.6)22 (33.3)35 (53.0)9 (13.6)11 (16.7)38 (57.6)17 (25.8)0.418, 0.8121.681, 0.4321.369, 0.504Histological type Tubular adenocarcinoma29 (38.7)34 (45.3)12 (16.0)23 (30.7)38 (50.7)14 (18.7)10 (13.3)40 (53.3)25 (33.3) Non-tubular adenocarcinoma6 (26.1)15 (65.2)2 (8.7)11 (47.8)10 (43.5)2 (8.7)4 (17.4)16 (69.6)3 (13.0)*χ* ^2^, *P*2.829, 0.2430.751, 0.2533.551, 0.169Differentiation Undifferentiated5 (33.3)10 (66.7)0 (0.0)8 (53.3)6 (40.0)1 (6.7)3 (20.0)9 (60.0)3 (20.0) Poor20 (33.3)29 (48.3)11 (18.3)19 (31.7)32 (53.3)9 (15.0)7 (11.7)34 (56.7)19 (31.7) Moderate9 (40.9)10 (45.5)3 (13.6)7 (31.8)10 (45.5)5 (22.7)4 (18.2)13 (59.1)5 (22.7) Well1 (100.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (100.0)0 (0.0)0 (0.0)1 (100.0)*χ* ^2^, *P*8.144, 0.2287.341, 0.2904.279, 0.639Growth patterns Expansive1 (50.0)1 (50.0)0 (0.0)2 (100.0)0 (0.0)0 (0.0)1 (50.0)1 (50.0)0 (0.0) Invasive24 (33.8)34 (47.9)13 (18.3)21 (29.6)36 (50.7)14 (19.7)9 (12.7)42 (59.2)20 (28.2) Expansive + invasive10 (40.0)14 (56.0)1 (4.0)10 (40.0)11 (44.0)12 (48.0)4 (16.0)13 (52.0)8 (32.0)*χ* ^2^, *P*4.443, 0.3497.200, 0.1262.694, 0.610Metastasis Yes14 (26.9)29 (55.8)9 (17.3)16 (30.8)26 (50.0)10 (19.2)5 (9.6)30 (57.7)17 (32.7) No21 (45.7)20 (43.5)5 (10.9)18 (39.1)22 (47.8)6 (13.0)9 (19.6)26 (56.5)11 (23.9)*χ* ^2^, *P*3.843, 0.1461.088, 0.5812.356, 0.308Depth of invasion T16 (42.9)8 (57.1)0 (0.0)5 (35.7)8 (57.1)1 (7.1)5 (35.7)5 (35.7)4 (28.6) T22 (40.0)2 (40.0)1 (20.0)1 (20.0)2 (40.0)2 (40.0)0 (0.0)4 (80.0)1 (20.0) T31 (33.3)1 (33.3)1 (33.3)0 (0.0)1 (33.3)2 (66.6)0 (0.0)1 (33.3)2 (66.6) T426 (34.2)38 (50.0)12 (15.8)28 (36.8)37 (48.7)11 (14.5)9 (11.8)46 (60.5)21 (27.6)*χ* ^2^, *P*5.469, 0.4857.900, 0.2469.263, 0.159Lymph node metastasis N022 (42.3)25 (48.1)5 (9.6)20 (38.5)26 (50.0)6 (11.5)9 (17.3)31 (59.6)12 (23.1) N16 (18.8)19 (59.4)7 (21.9)10 (31.3)14 (43.8)8 (25.0)4 (12.8)17 (53.1)11 (34.4) N25 (45.5)4 (36.4)2 (18.2)4 (36.4)5 (45.5)2 (18.2)0 (0.0)8 (72.7)3 (27.3)Undetermined2 (66.7)1 (33.3)0 (0.0)0 (0.0)3 (100.0)0 (0.0)1 (33.3)0 (0.0)2 (66.7)*χ* ^2^, *P*8.812, 0.1846.938, 0.32710.139, 0.119Distant metastasis M031 (36.0)41 (51.2)11 (12.8)33 (38.4)39 (45.3)14 (16.3)12 (14.0)51 (59.3)23 (26.7) M14 (33.3)5 (41.7)3 (25.0)1 (8.39 (75.0)2 (16.7)2 (16.7)5 (41.7)5 (41.7)*χ* ^2^, *P*1.148, 0.5635.461, 0.0651.410, 0.494TNM staging I8 (44.4)9 (50.0)1 (5.6)6 (33.3)9 (50.0)3 (16.7)5 (27.8)8 (44.4)5 (27.8) IIA-IIC11 (37.9)15 (51.7)3 (10.3)11 (37.9)15 (51.7)3 (10.3)3 (10.3)20 (69.0)6 (20.7) IIIA-IIIC12 (30.8)20 (51.3)7 (17.9)16 (41.0)15 (38.5)8 (20.5)4 (10.3)23 (59.0)12 (30.8) IVA-IVB4 (33.3)5 (41.7)3 (25.0)1 (8.3)9 (75.0)2 (16.7)2 (16.7)5 (41.7)5 (41.7)*χ* ^2^, *P*3.629, 0.7277.539, 0.2745.869, 0.438The values in bold indicate the statistically significant difference

UGT1A1 polymorphisms and their relationships with clinical characteristics {#Sec10}
--------------------------------------------------------------------------

There were no significant differences in the genotype distribution between patients with different gender, age, family history, alcohol history, differentiation degree, growth patterns, metastasis and TNM staging (Table [4](#Tab4){ref-type="table"}). The genotype frequencies for the UGT1A1 polymorphism at position −211 were associated with the histological type, in which patients with GG genotype showed a predisposition to developing tubular adenocarcinoma. In addition, polymorphisms at positions \*28 and −3156 were correlated with the depth of invasion (both *P* = 0.023) where patients carrying 6TAA or G allele tended to have a local invasion. Combined effects for UGT1A1\*28, UGT1A1-211 and UGT1A1-3156 were also performed and the results only indicated the association with the histological type (*P* = 0.043) (Table [5](#Tab5){ref-type="table"}).Table 4UGT1A11 polymorphisms and their relationships with clinical characteristicsClinical features\*28−3156 GA211GATA 6/6TA 6/7TA 7/7GGGAAAGGGAAAGender Male64 (84.2)10 (13.2)2 (2.6)64 (84.2)10 (13.2)2 (2.6)49 (64.5)23 (30.3)4 (5.3) Female17 (77.3)5 (22.7)0 (0.0)17 (77.3)5 (22.7)0 (0.0)13 (59.1)9 (40.9)0 (0.0)*χ* ^2^, *P*2.046, 0.3592.046, 0.3592.674, 0.263Age  \< 57 years33 (80.5)8 (19.5)0 (0.0)33 (80.5)8 (19.5)0 (0.0)26 (63.4)14 (34.1)1 (2.4)  \> 57 years48 (84.2)7 (12.3)2 (3.5)48 (84.2)7 (12.3)2 (3.5)36 (63.2)18 (31.6)3 (5.3)*χ* ^2^, *P*3.009, 0.2223.009, 0.2220.544, 0.762Family history Yes4 (80.0)1 (20.0)0 (0.0)4 (80.0)1 (20.0)0 (0.0)2 (40.0)2 (40.0)1 (20.0) No77 (82.8)14 (15.1)2 (2.2)77 (82.8)14 (15.1)2 (2.2)60 (64.5)30 (62.3)3 (3.2)*χ* ^2^, *P*0.283, 0.8680.283, 0.8682.364, 0.307Alcohol history Yes29 (90.6)3 (9.4)0 (0.0)29 (90.6)3 (9.4)0 (0.0)21 (65.6)9 (28.1)2 (6.3) No52 (78.8)12 (18.2)2 (3.0)52 (78.8)12 (18.2)2 (3.0)41 (62.1)23 (34.8)2 (3.0)*χ* ^2^, *P*3.132, 0.2093.132, 0.2090.861, 0.650Histological type Tubular adenocarcinoma60 (80.0)13 (17.3)2 (2.7)60 (80.0)13 (17.3)2 (2.7)54 (72.0)19 (25.3)2 (2.7) Non-tubular adenocarcinoma21 (91.3)2 (8.7)0 (0.0)21 (91.3)2 (8.7)0 (0.0)8 (34.8)13 (56.5)2 (8.7)*χ* ^2^, *P*2.308, 0.3152.308, 0.31510.339, **0.006**Differentiation Undifferentiated13 (86.7)2 (13.3)0 (0.0)13 (86.7)2 (13.3)0 (0.0)6 (40.0)7 (46.7)2 (13.3) Poor51 (85.0)8 (13.3)1 (1.7)51 (85.0)8 (13.3)1 (1.7)41 (68.3)18 (30.0)1 (1.7) Moderate17 (77.3)4 (18.2)1 (4.5)17 (77.3)4 (18.2)1 (4.5)14 (63.6)7 (31.8)1 (4.5) Well0 (0.0)1 (100.0)0 (0.0)0 (0.0)1 (100.0)0 (0.0)1 (100.0)0 (0.0)0 (0.0)*χ* ^2^, *P*5.368, 0.4985.368, 0.4986.642, 0.355Growth patterns Expansive2 (100.0)0 (0.0)0 (0.0)2 (100.0)0 (0.0)0 (0.0)1 (50.0)1 (50.0)0 (0.0) Invasive56 (78.9)13 (18.3)2 (2.8)56 (78.9)13 (18.3)2 (2.8)47 (66.2)21 (29.6)3 (4.2) Expansive + invasive23 (92.0)2 (8.0)0 (0.0)23 (92.0)2 (8.0)0 (0.0)14 (56.0)10 (40.0)1 (4.0)*χ* ^2^, *P*3.800, 0.4343.800, 0.4341.295, 0.862*χ* ^2^, *P*1.239, 0.5381.239, 0.5382.959, 0.228Depth of invasion T111 (78.6)1 (7.1)2 (14.2)11 (78.6)1 (7.1)2 (14.2)11 (78.6)3 (21.4)0 (0.0) T22 (40.0)3 (60.0)0 (0.0)2 (40.0)3 (60.0)0 (0.0)4 (80.0)1 (20.0)0 (0.0) T32 (66.7)1 (33.3)0 (0.0)2 (66.7)1 (33.3)0 (0.0)3 (100.0)0 (0.0)0 (0.0) T466 (86.8)10 (13.2)0 (0.0)66 (86.8)10 (13.2)0 (0.0)44 (57.9)28 (36.8)4 (5.3)*χ* ^2^, *P*14.637, **0.023**14.637, **0.023**6.870, 0.333Lymph node metastasis N041 (78.8)10 (19.2)1 (1.9)41 (78.8)10 (19.2)1 (1.9)35 (67.3)16 (30.8)1 (1.9) N126 (81.3)5 (15.6)1 (3.1)26 (81.3)5 (15.6)1 (3.1)21 (65.6)9 (28.1)2 (6.3) N211 (100)0 (0.0)0 (0.0)11 (100)0 (0.0)0 (0.0)3 (27.3)7 (63.6)1 (9.1)Undetermined3 (100.0)0 (0.0)0 (0.0)3 (100.0)0 (0.0)0 (0.0)3 (100.0)0 (0.0)0 (0.0)*χ* ^2^, *P*6.082, 0.4146.082, 0.41410.126, 0.119Distant metastasis M069 (80.2)15 (17.4)2 (2.3)69 (80.2)15 (17.4)2 (2.3)57 (66.3)25 (29.1)4 (4.7) M112 (100)0 (0.0)0 (0.0)12 (100)0 (0.0)0 (0.0)5 (41.7)7 (58.3)0 (0.0)*χ* ^2^, *P*4.912, 0.0864.912, 0.0864.485, 0.106TNM staging I13 (72.2)3 (16.7)2 (11.1)13 (72.2)3 (16.7)2 (11.1)14 (77.8)4 (22.2)0 (0.0) IIA-IIC23 (79.3)6 (20.7)0 (0.0)23 (79.3)6 (20.7)0 (0.0)22 (75.9)6 (20.7)1 (3.4) IIIA-IIIC33 (84.6)6 (15.4)0 (0.0)33 (84.6)6 (15.4)0 (0.0)21 (53.8)15 (38.5)3 (7.7) IVA-IVB12 (100)0 (0.0)0 (0.0)12 (100)0 (0.0)0 (0.0)5 (41.7)7 (58.3)0 (0.0)*χ* ^2^, *P*11.682, 0.06911.682, 0.06910.771, 0.096The values in bold indicate the statistically significant difference Table 5UGT1A11 polymorphisms and their relationships with clinical characteristics (Continued Table 4)Clinical featuresCombinationTA6/6 −3156GG, 211GGTA6/6, −3156GG, 211GATA6/7, −3156GA, 211GGTA6/7, −3156GA, 211GATA6/6, −3156GG, 211AATA7/7, −3156AA, 211GGGender Male39 (51.3)21 (27.6)8 (10.5)2 (2.6)4 (5.3)2 (2.6) Female8 (36.4)9 (40.9)5 (22.7)0 (0.0)0 (0.0)0 (0.0)*χ* ^2^, *P*7.516, 0.185Age  \< 57 years19 (46.3)13 (31.7)7 (17.1)1 (2.4)1 (2.4)0 (0.0)  \> 57 years28 (49.1)17 (29.8)6 (10.5)1 (1.8)3 (5.3)2 (3.5)*χ* ^2^, *P*3.541, 0.617Family history Yes1 (20.0)2 (40.0)1 (20.0)0 (0.0)1 (20.0)0 (0.0) No46 (49.5)28 (30.1)12 (12.9)2 (2.2)3 (3.2)2 (2.2)*χ* ^2^, *P*3.571, 0.613Alcohol history Yes18 (56.3)9 (28.1)3 (9.4)0 (0.0)2 (6.3)0 (0.0) No29 (43.9)21 (31.8)10 (15.2)2 (3.0)2 (3.0)2 (3.0)*χ* ^2^, *P*7.516, 0.185Histological type Tubular adenocarcinoma40 (53.3)18 (24.0)12 (16.0)1 (1.3)2 (2.7)2 (2.7) Non-tubular adenocarcinoma7 (30.4)12 (52.2)1 (4.3)1 (4.3)2 (8.7)0 (0.0)*χ* ^2^, *P*11.488, **0.043**Differentiation Undifferentiated5 (33.3)6 (40.0)1 (6.7)1 (6.7)2 (13.3)0 (0.0) Low32 (53.3)18 (30.0)8 (13.3)0 (0.0)1 (1.7)1 (1.7) Moderate10 (45.5)6 (27.3)3 (13.6)1 (4.5)1 (4.5)1 (4.5) High0 (0.0)0 (0.0)1 (100.0)0 (0.0)0 (0.0)0 (0.0)*χ* ^2^, *P*14.419, 0.494Growth patterns Expansive1 (50.0)1 (50.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0) Invasive34 (47.9)19 (26.8)11 (15.5)2 (2.8)3 (4.2)2 (2.8) Expansive + invasive12 (48.0)10 (40.0)2 (8.0)0 (0.0)1 (4.0)0 (0.0)*χ* ^2^, *P*5.361, 0.866Metastasis Yes23 (44.2)19 (36.5)5 (9.6)1 (1.9)3 (5.8)1 (1.9) No24 (52.2)11 (23.9)8 (17.4)1 (2.2)1 (2.2)1 (2.2)*χ* ^2^, *P*3.558, 0.615Depth of invasion T18 (57.1)3 (21.4)1 (7.1)0 (0.0)0 (0.0)2 (14.3) T21 (20.0)1 (20.0)3 (60.0)0 (0.0)0 (0.0)0 (0.0) T32 (66.7)0 (0.0)1 (33.3)0 (0.0)0 (0.0)0 (0.0) T436 (47.4)26 (34.2)8 (10.5)2 (2.6)4 (5.3)0 (0.0)*χ* ^2^, *P*21.061, 0.135Lymph node metastasis N025 (48.1)15 (28.8)9 (17.3)1 (1.9)1 (1.9)1 (1.9) N116 (50.0)8 (25.0)4 (12.5)1 (3.1)2 (6.3)1 (3.1) N23 (27.3)7 (63.6)0 (0.0)0 (0.0)1 (9.1)0 (0.0) Undetermined3 (100.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)*χ* ^2^, *P*15.280, 0.431Distant metastasis M042 (48.8)23 (26.7)13 (15.1)2 (2.3)4 (4.7)2 (2.3) M15 (41.7)7 (58.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)*χ* ^2^, *P*8.417, 0.135TNM staging I9 (50.0)4 (22.2)3 (16.7)0 (0.0)0 (0.0)2 (11.1) IIA-IIC16 (55.2)6 (20.7)6 (20.7)0 (0.0)1 (3.4)0 (0.0) IIIA-IIIC17 (43.6)13 (33.3)4 (10.3)2 (5.1)3 (7.7)0 (0.0) IVA-IVB5 (41.7)7 (58.3)0 (0.0)0 (2.6)0 (5.3)0 (0.0)*χ* ^2^, *P*23.131, 0.081The values in bold indicate the statistically significant difference

Discussion {#Sec11}
==========

Individualized therapeutic regimen is a recently intensively pursued approach for targeting diseases at the molecular level, in which the search for biomarkers was considered the first and most important \[[@CR28], [@CR29]\]. Therefore, the present study was to investigate whether the genes ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A are underlying biomarkers for patients with gastric cancer, which, to our knowledge, has not been performed. However, our results showed that only the expression levels of TYMS, TUBB3 and STMN1 were significantly associated with the clinical characteristics of age, gender and family history of gastric cancer, but not with differentiation degree, growth patterns, metastasis and TNM staging in patients with gastric cancer. No clinical characteristics were correlated with the expressions of ERCC1, BRCA1, RRM1 and TOP2A. These findings seemed not to be fully in accordance with the studies of other cancers \[[@CR3]--[@CR8]\], suggesting the difference among different cancers.

TUBB3 is one of the major components of microtubules (a basic constructive unit of spindle) to be involved in cell division, thus promoting the possibility of malignant growth and metastases \[[@CR30]\]. As expected, TUBB3 is shown to be higher expressed in various cancers than that in healthy control, including gastric cancer (31.6 ± 17.8 ng/mL vs. 16.9 ± 3.8 ng/mL, *p* \< 0.001) \[[@CR31]\]. To reduce the expression of TUBB3 and improve survival of cancer patients, several anti-microtubule chemotherapeutic agents (i.e. paclitaxel, capecitabine, carboplatin) were suggested and the studies demonstrated that the patients were more sensitive to these treatments when TUBB3 mRNA expression was low enough \[[@CR31]--[@CR34]\]. In this study, we found TUBB3 was relatively lower expressed in the females (*P* = 0.026), patients with age \< 57 years (*P* = 0.024) and family history of gastric cancer (*P* = 0.025), suggesting the above anti-microtubule chemotherapeutic agents should be recommended for these patients to obtain more benefits.

STMN1 encodes a regulatory protein that participates in assembly and disassembly of the mitotic spindle, facilitating the achievement of mitosis process and uncontrolled proliferation of malignant tumor cells \[[@CR35]\]. Hence, STMN1 should be also highly expressed in gastric cancer, which has been demonstrated by the study of Kang et al. who report an up-regulated expression of STMN1 in 80 and 56% primary gastric adenocarcinomas at protein and mRNA levels, respectively \[[@CR36]\]. Knock-down of STMN1 using siRNA inhibits the proliferation, migration and invasion of gastric cancer cells and slows the growth of xenografts in nude mice \[[@CR37]--[@CR39]\]. Although STMN1 over-expression has been reported to be positively correlated with lymph node metastasis and TNM staging \[[@CR36], [@CR37], [@CR40]\], no association was proved in our study, which may be attributed to small sample size and different detection methods. Moreover, studies imply that cancer patients with low expression of STMN1 mRNA will have a favorable clinical efficacy after being treated with Taxol regimens \[[@CR41], [@CR42]\]. Silencing STMN1 enhances the sensitivity of gastric cancer cells to docetaxel, with the resistance index reducing to 3.41 \[[@CR13]\]. In this study, we found STMN1 was relatively lower expressed in the patients with age \< 57 years (*P* = 0.042), suggesting Taxol and docetaxel may be a more appropriate treatment for patients aged \< 57 years.

TYMS is a central enzyme in the folate metabolic pathway, which catalyzes the conversion of deoxyuridine monophosphate to deoxythymidine monophosphate, thereby maintaining the dTMP (thymidine-5-prime monophosphate) pool critical for DNA replication and repair. Tumor cells with higher TYMS expression exhibited higher proliferative and metastatic activities due to its accelerated effect on the DNA replication \[[@CR43], [@CR44]\]. Thus, scholars suggest TYMS may be a potential biomarker for gastric cancer and response rates for the antifolate cytotoxic chemotherapy (i.e. raltitrexed, fluoropyrimidine) may be higher in patients with low expression of TYMS \[[@CR45], [@CR46]\].

Moreover, we also investigated whether the genetic variation in UGT1A1 gene was related with the clinical characteristics of gastric cancer, which, to our knowledge, has also not been performed. The results showed that patients carrying G allele at −211 were predisposed to developing tubular adenocarcinoma, while patients carrying 6TAA or G allele respectively at \*28 and −3156 tended to have a local invasion. Our results are similar to previous studies because the -211GG, −211GA, \*28 6TAA/6TAA, \*28 6TAA/7TAA, −3156 GG or −3156 GA contribute to high expression of UGT1A1 gene, which causes high levels of glucuronidation and then reduces serum bilirubin levels. Lower bilirubin did not exert protective effects against cancer development and progression by inhibiting cellular damage induced by oxidative stress \[[@CR26], [@CR47]\]. Therefore, bilirubin levels should be moderately elevated to improve the overall survival of these patients \[[@CR48]\].

Our study had some limitations. Firstly, this was a single institutional study and sample size was not enough large, which may result in different conclusions with previous studies. Secondly, the gene expression was only detected using the multiplex branched DNA liquidchip technology, but not confirmed by immunohistochemistry with normal stomach tissues or para-carcinoma tissues as control. However, we believe our study may be important because the expression level (low, middle, high) detected by the MBL technology may be more effective to guide the prognosis and individualized chemotherapy as previously described \[[@CR3]--[@CR8]\]. The studies about comparison with normal stomach tissues or para-carcinoma tissues only indicate the upregulation or downregulation, but not further classify the degree. Furthermore, the expression of 7 genes in comparison with normal stomach or adjacent normal has been independently investigated previously \[[@CR9]--[@CR15]\]. Thirdly, gastric cancer samples were only categorized according to the WHO's, but not by the Lauren's histological classification system in our hospital. However, recent studies indicate there is a high concordance between two systems \[[@CR49], [@CR50]\]. Fourthly, chemotherapy and follow up results had not been collected completely, although they have been performed in our center. This resulted in the lack of analysis on cost effectiveness ratio, which may be the most concern for patients. Nevertheless, we believe the average cost effectiveness ratio may be lower because our detection can guide the individualized chemotherapy arrangement, which may be beneficial to 1) improve the efficacy and prolong life; 2) reduce the side effect due to the inappropriate chemotherapy drugs, and enhance the quality of life; 3) prevent a waste of money due to the repeated attempts of chemotherapy drugs/scheme. In summary, further investigation is still essential to confirm the biomarker role of TYMS, TUBB3, STMN1 and UGT1A1 by a multicenter clinical study with large sample size, more classification systems, addition of control samples, immunohistochemistry confirmation and chemotherapy results.

Conclusions {#Sec12}
===========

Our findings suggest UGT1A1 polymorphisms may be useful to screen the risk population of gastric cancer and schedule the appropriate pretreatment to improve the overall survival, while TYMS, TUBB3 and STMN1 may be potential biomarkers for prognosis and chemotherapy guidance.

Additional file {#Sec13}
===============

Additional file 1:Raw data of patients. The general characteristics, gene expressions and polymorphisms of each patient are available. (XLS 54 kb)
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